Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (GB:0TDD)
LSE:0TDD
Holding GB:0TDD?
Track your performance easily
0TDD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$86.97 - $149.80
Previous Close$137.27
Volume3.31K
Average Volume (3M)31.37K
Market Cap
$606.73B
Enterprise Value$606.24B
Total Cash (Recent Filing)kr30.23B
Total Debt (Recent Filing)kr27.01B
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Nov 06, 2024EPS Estimate
$0.89Last Dividend Ex-Date
Aug 16, 2024Dividend Yield0.71%
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,462,229,293
10 Day Avg. Volume5,825
30 Day Avg. Volume31,367
Standard Deviation0.06
R-Squared0.01
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)89.84
Price to Sales (P/S)17.85
Price to Cash Flow (P/CF)108.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$144.75Price Target Upside5.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Novo Nordisk News
PremiumStock Analysis & Ideas
LLY, NVO: Which GLP-1 Stock Is the Better Bet?
PremiumCompany Announcements
Novo Nordisk Executives Trade Company Shares
PremiumCompany Announcements
Novo Nordisk Initiates Multi-Billion Share Buyback
Bulls Say, Bears Say
Bulls Say
Pipeline And DataPipeline readouts offer multiple shots on goal for investors, emphasizing significance for Novo and competitors in the space.
Product DemandNovo's top priority is meeting the demand for incretin products: Ozempic and Wegovy.
Revenue GuidanceRev guidance raise to 22–28% YoY-growth at CER, reinforces confidence in upside for Novo.
Bears Say
Clinical TrialsAcquired asset, ocedurenone, fails in pre-specified interim analysis for Ph 3 CLARION-CKD trial.
Research And DevelopmentHigher-than-expected R&D expense included a DKK 5.7B ocedurenone impairment contributing to a bottom line miss.
Supply ConstraintsObesity Care notably underperformed with Wegovy still impacted by supply constraints amidst strong demand.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
1.63% Mutual Funds
5.03% Other Institutional Investors
93.34% Public Companies and
Individual Investors
0TDD FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest share price was $86.97 and its highest was $149.80 in the past 12 months.
What is Novo Nordisk’s market cap?
Currently, no data Available
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Nov 06, 2024 which is in 73 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Aug 07, 2024. The company reported $0.658 earnings per share for the quarter, missing the consensus estimate of $0.708 by -$0.05.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $0.37 which represents an annual dividend yield of 0.71%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is $0.89.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.658 in its last earnings report, missing expectations of $0.708. Following the earnings report the stock price went down -6.715%.
Which hedge fund is a major shareholder of Novo Nordisk?
Among the largest hedge funds holding Novo Nordisk’s share is Fisher Asset Management LLC. It holds Novo Nordisk’s shares valued at 2B.
---
Novo Nordisk Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$144.75 (5.45% Upside)
$144.75 (5.45% Upside)
Blogger Sentiment
Bullish
GB:0TDD Sentiment 84%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.26%
12-Months-Change
Fundamentals
Return on Equity
88.62%
Trailing 12-Months
Asset Growth
29.05%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S is a Denmark-based healthcare company, which manufactures and markets pharmaceutical products globally. The company operates through two segments, including Diabetes & Obesity Care, and Biopharmaceuticals. The company was founded in 1925.
---
0TDD Company Deck
---
0TDD Earnings Call
Q2 2024
0:00 / 0:00
---
0TDD Stock 12 Month Forecast
Average Price Target
$144.75
▲(5.45% Upside)
Technical Analysis
Best Analysts Covering 0TDD
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+25.19%
reiterated a buy rating 18 days ago
Copying Michael Nedelcovych's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +25.19% per trade.
---